ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. is Fair to Shareholders

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the proposed sale of Adverum Biotechnologies, Inc. to Eli Lilly and Company for Adverum shareholders, focusing on the adequacy of the offered compensation and the board's fiduciary duties [1][3]. Group 1: Transaction Details - Adverum shareholders are set to receive $3.56 per share in cash, along with a non-transferrable contingent value right (CVR) that could yield up to an additional $8.91 per CVR upon achieving specific milestones [1]. Group 2: Legal Investigation - The investigation aims to determine if Adverum and its board violated federal securities laws or breached fiduciary duties by not securing the best possible consideration for shareholders, assessing whether Eli Lilly is underpaying, and failing to disclose all material information necessary for shareholders to evaluate the merger [3]. Group 3: Potential Actions - Halper Sadeh LLC may pursue increased compensation for shareholders, additional disclosures, and other forms of relief related to the proposed transaction [4].